Rituxan is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Genentech, Inc.. The primary component is Rituximab.
Product ID | 50242-051_02e8a40e-4443-4bd5-acff-ad7f3244d43c |
NDC | 50242-051 |
Product Type | Human Prescription Drug |
Proprietary Name | Rituxan |
Generic Name | Rituximab |
Dosage Form | Injection, Solution |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 1997-11-26 |
Marketing Category | BLA / BLA |
Application Number | BLA103705 |
Labeler Name | Genentech, Inc. |
Substance Name | RITUXIMAB |
Active Ingredient Strength | 10 mg/mL |
Pharm Classes | CD20-directed Antibody Interactions [MoA],CD20-directed Cytolytic Antibody [EPC] |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2019-06-03 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA103705 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2019-06-03 |
Marketing Category | BLA |
Application Number | BLA103705 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 1997-11-26 |
Ingredient | Strength |
---|---|
RITUXIMAB | 10 mg/mL |
SPL SET ID: | b172773b-3905-4a1c-ad95-bab4b6126563 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
50242-051 | Rituxan | rituximab |
50242-053 | Rituxan | rituximab |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
RITUXAN 75238749 2194252 Live/Registered |
BIOGEN MA INC. 1997-02-10 |